Skip to main content

Biogen Alzheimer's Collaboration revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Alzheimer's Collaboration revenue at Biogen came to $68.4M for the quarter to 30 Sep 2026, up 60.2% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$2.8MMar 2024$11.8MJun 2024$18.6MSep 2024$26.7MDec 2024$33.0MMar 2025$54.9MJun 2025$42.7MSep 2025$47.1MDec 2025$59.5MMar 2026$63.7MJun 2026$68.4MSep 2026
Biogen Alzheimer's Collaboration revenue, every reported period
Period endingAlzheimer's Collaboration revenueChange on a yearFiled
30 Sep 2026$68.4Mup 60.2%28 Oct 2026
30 Jun 2026$63.7Mup 16.0%29 Jul 2026
31 Mar 2026$59.5Mup 80.3%29 Apr 2026
31 Dec 2025$47.1Mup 76.4%6 Feb 2026
30 Sep 2025$42.7Mup 129.6%30 Oct 2025
30 Jun 2025$54.9Mup 365.3%31 Jul 2025
31 Mar 2025$33.0Mup 1078.6%1 May 2025
31 Dec 2024$26.7M—12 Feb 2025
30 Sep 2024$18.6M—30 Oct 2024
30 Jun 2024$11.8M—1 Aug 2024
31 Mar 2024$2.8M—24 Apr 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.